Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pluristem Therapeutics Inc (NASDAQ:PSTI)

1.88
Delayed Data
As of 3:59pm ET
 -0.02 / -1.05%
Today’s Change
1.84
Today|||52-Week Range
3.78
-24.80%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$149.2M

Company Description

Pluristem Therapeutics, Inc. engages in the development of standardized cell therapy products for the treatment of life threatening diseases. Its patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. It offers to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The company was founded on May 11, 2001 and is headquartered in Haifa, Israel.

Contact Information

Pluristem Therapeutics, Inc.
MATAM Advanced Technology Park
Haifa Haifa 31905
P:972747107171
Investor Relations:
972747108721

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Zami AbermanChairman & Chief Executive Officer
Yaky YanayPresident & Chief Operating Officer
Boaz Gur-LavieChief Financial Officer & Secretary
Esther Lukasiewicz-HagaiVice President-Clinical & Medical Affairs
Ohad KarnieliVice President-Technology & Manufacturing